COSMOS Pharmaceutical Corporation
3349株式会社コスモス薬品
Latest half-year results
First half · fiscal year to 2026-05 · filed 2026-01-14For the first half of the fiscal year to 2026-05: Revenue ¥537.2 billion (+6.2% YoY), Ordinary income ¥21.9 billion (+0.7% YoY), Net income ¥14.6 billion (+1.5% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥537.2bn | +6.2% |
| Ordinary profit | ¥21.9bn | +0.7% |
| Net profit to owners | ¥14.6bn | +1.5% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/3349/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2026-05-31- Revenue
- ¥1.1tn
- Net income
- ¥32.0bn
- ROE
- 11.8%
- Equity ratio
- 47.6%
- Dividend / share
- ¥82
- Employees
- 5,984
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | ¥1,099.6bn | ¥32.0bn | ¥596.5bn | ¥283.7bn | 11.8% | ¥404.33 | ¥58.8bn |
| 2025-05-31 | ¥1,011.4bn | ¥31.0bn | ¥524.8bn | ¥257.5bn | 12.7% | ¥390.86 | ¥52.5bn |
| 2024-05-31 | ¥965.0bn | ¥24.5bn | ¥476.5bn | ¥231.4bn | 11.1% | ¥308.61 | ¥55.2bn |
| 2023-05-31 | ¥827.7bn | ¥23.8bn | ¥421.0bn | ¥211.1bn | 11.9% | ¥600.96 | ¥54.4bn |
| 2022-05-31 | ¥755.4bn | ¥23.2bn | ¥363.1bn | ¥190.5bn | 12.8% | ¥584.76 | ¥32.2bn |
Indicators
Computed by us from filings · fiscal year to 2026-05-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 11.8 | 67 |
| Ordinary margin | 0.0406 | 31.6 |
| Equity ratio, % | 47.6 | 38.1 |
| Revenue growth | 0.0872 | 65.5 |
| Net income growth | 0.0345 | 39.2 |
| Operating cash flow / assets | 0.0986 | 72.1 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥70.7bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥353m, 0.6% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/3349/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/3349/votingOwnership changes
All companies →- 2026-10-07
Baillie Gifford & Co reduced holdings in COSMOS Pharmaceutical Corporation (3349) to 6.62% from 7.65%.
- 2026-09-04
Nomura Securities Co.,Ltd. reduced holdings in COSMOS Pharmaceutical Corporation (3349) to 5.86% from 6.88%.
- 2026-05-13
BANRYOKU Co., Ltd. raised holdings in COSMOS Pharmaceutical Corporation (3349) to 41.47% from 38.29%.
- 2026-04-21
NOMURA INTERNATIONAL PLC raised holdings in COSMOS Pharmaceutical Corporation (3349) to 6.88% from 5.95%.
- 2026-02-19
Baillie Gifford & Co raised holdings in COSMOS Pharmaceutical Corporation (3349) to 7.65% from 6.66%.
- 2025-12-22
NOMURA INTERNATIONAL PLC disclosed a 5.95% stake in COSMOS Pharmaceutical Corporation (3349), crossing the 5% reporting threshold.
- 2025-12-03
JPMorgan Asset Management (Japan) Limited cut holdings in COSMOS Pharmaceutical Corporation (3349) to 3.69% from 5.18%, below the 5% threshold.
- 2025-11-05
JPMorgan Asset Management (Japan) Limited raised holdings in COSMOS Pharmaceutical Corporation (3349) to 5.18% from 5.13%.
- 2025-09-19
Baillie Gifford & Co reduced holdings in COSMOS Pharmaceutical Corporation (3349) to 6.66% from 7.71%.
- 2025-06-18
JPMorgan Asset Management (Japan) Limited disclosed a 5.13% stake in COSMOS Pharmaceutical Corporation (3349), crossing the 5% reporting threshold.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| 有限会社萬緑 | 2024-09-01 – 2024-09-01 | 0 | 0.00pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/3349/trades.
5% filings
Large shareholding reports on 3349| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-10-07 | Baillie Gifford & Co | 6.62% | −1.03pt | — |
| 2026-09-04 | Nomura Securities Co.,Ltd. | 5.86% | −1.02pt | — |
| 2026-05-13 | BANRYOKU Co., Ltd. | 41.47% | +3.18pt | — |
| 2026-04-21 | NOMURA INTERNATIONAL PLC | 6.88% | +0.93pt | — |
| 2026-02-19 | Baillie Gifford & Co | 7.65% | +0.99pt | — |
| 2025-12-22 | NOMURA INTERNATIONAL PLC | 5.95% | — | — |
| 2025-12-03 | JPMorgan Asset Management (Japan) Limited | 3.69% | −1.49pt | pure investment |
| 2025-11-05 | JPMorgan Asset Management (Japan) Limited | 5.18% | +0.05pt | pure investment |
| 2025-09-19 | Baillie Gifford & Co | 6.66% | −1.05pt | — |
| 2025-07-24 | BANRYOKU Co., Ltd. | 38.29% | 0.00pt | — |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 5 issues
- Book value
- ¥1m
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 19
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| TSURUHA HOLDINGS INC. 3391 | ¥0m | 0.0% | no |
| SUGI HOLDINGS CO.,LTD. 7649 | ¥0m | 0.0% | no |
| SUNDRUG CO.,LTD. 9989 | ¥0m | 0.0% | no |
| CREATE SD HOLDINGS CO.,LTD 3148 | ¥0m | 0.0% | no |
| CAWACHI LIMITED 2664 | ¥0m | 0.0% | no |
Held by: S.T.CORPORATION 4951, FUMAKILLALIMITED 4998, 8283 8283, KOSE Holdings Corporation 4922, ARATA CORPORATION 2733, SAPPORO BREWERIES LIMITED 2501, Kirin Holdings Company, Limited 2503, DAIWA HOUSE INDUSTRY CO., LTD. 1925, YAMAE GROUP HOLDINGS CO.,LTD. 7130, MARUDAI FOOD CO.,LTD. 2288, Calbee, Inc. 2229, OHKI HEALTHCARE HOLDINGS CO.,LTD. 3417 and 7 more
Purposes, all holdings and mutual flags via /v1/companies/3349/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-05-31| Shareholder | Shares | Ratio |
|---|---|---|
| 有限会社萬緑 | 30,636,000 | 38.65% |
| 日本マスタートラスト信託銀行株式会社（信託口） | 6,286,000 | 7.93% |
| 株式会社日本カストディ銀行（信託口） | 3,269,000 | 4.13% |
| 公益財団法人余慶会 | 3,000,000 | 3.79% |
| 管理信託（A036）受託者 株式会社SMBC信託銀行 | 2,400,000 | 3.03% |
| 管理信託（A037）受託者 株式会社SMBC信託銀行 | 2,052,000 | 2.59% |
| 管理信託（A038）受託者 株式会社SMBC信託銀行 | 2,051,000 | 2.59% |
| コスモス薬品従業員持株会 | 1,569,000 | 1.98% |
| individual holder | 1,498,000 | 1.89% |
| STATE STREET BANK AND TRUST COMPANY 505001 | 937,000 | 1.18% |
U.S. funds holding 3349
SEC Form N-PORT, reports to 2026-07-3176 U.S. funds held 3,652,244 shares worth $144.2m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 553,446 | $22.3m | 0.003% | 2026-07-31 |
| VANGUARD GLOBAL EQUITY FUND VANGUARD HORIZON FUNDS | 451,200 | $17.1m | 0.226% | 2026-06-30 |
| Fidelity Low-Priced Stock Fund Fidelity Puritan Trust | 356,324 | $14.4m | 0.058% | 2026-07-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 367,808 | $14.0m | 0.004% | 2026-06-30 |
| iShares Core MSCI EAFE ETF iShares Trust | 259,200 | $10.5m | 0.005% | 2026-07-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/3349
GET /v1/companies/3349/financials
GET /v1/companies/3349/details
GET /v1/companies/3349/segments
GET /v1/companies/3349/voting
GET /v1/companies/3349/tender-offers
GET /v1/companies/3349/indicators
GET /v1/companies/3349/earnings-releases
GET /v1/events?ticker=3349
GET /v1/companies/3349/trades
GET /v1/companies/3349/cross-holdings
GET /v1/companies/3349/brief